IL-4 and IL-13 are related cytokines which induce both pro-and anti-in¯ammatory eects depending on the cell type they act upon and the nature of the receptors expressed. The type I receptor complex is composed of the IL-4Ra and gc and only binds IL-4, whereas, in the type II receptor, IL-4Ra dimerizes with IL-13Ra1 upon either IL-4 or IL-13 binding. Another ligand binding chain potentially implicated in the IL-4/IL-13 receptor has been described, the IL-13Ra2, but the regulation of its expression and its role in IL-4/IL-13 transduction is poorly understood. In this study we report that IL-4 and IL-13 upregulate IL-13Ra2 at both the mRNA and protein levels in the keratinocyte cell line HaCaT. In these cells, IL-4 or IL-13 were shown to activate the Janus Kinases JAK1 and JAK2, the transcription factor STAT6, and the ERK and p38 mitogen-activated protein kinases. We show that IL-4 or IL-13-induced IL-13Ra2 mRNA expression was inhibited by the ERK inhibitor U0126, the JAK inhibitor AG490 and, to a lesser extent, the p38 MAPK inhibitor SB203580. Moreover, expression of a constitutive active mutant of STAT6 alone did not modify IL-13Ra2 mRNA expression, but potentiated the eects of IL-4 or IL-13 on IL-13Ra2 expression. The constitutive active mutants of MEK1 or MKK6 increased the level of expression of IL-13Ra2 mRNA even in absence of stimulation. Our ®ndings demonstrate, for the ®rst time, that IL-4 and IL-13 can induce IL-13Ra2 expression in keratinocytes, and that the ERK and p38 MAPK together with JAK2 and STAT6 play a critical role in this process. Oncogene (2001) 20, 6660 ± 6668.
Introduction
IL-4 and IL-13 are two cytokines expressed and secreted mainly by activated Th-2 lymphocytes and mastocytes (Minty et al., 1993; Yokota et al., 1986) . Despite their limited sequence homology (30% identity), IL-4 and IL-13 are structurally and functionally related, and are critical in regulating some in¯amma-tory and immune responses. Both cytokines promote IgE isotype switching, enhance the expression of MHC class II antigens on B cells, and down-regulate proin¯ammatory cytokines and chemokines expression by monocytes (Defrance et al., 1994; Minty et al., 1993) . IL-4 and IL-13 also have pro-in¯ammatory eects on other cell types. In particular, IL-4 and IL-13 enhance IL-6 expression by endothelial cells and keratinocytes (Colotta et al., 1992; Derocq et al., 1994) . These overlapping activities of IL-4 and IL-13 are conferred by the existence of common receptor components. The IL-4 receptor a-chain (IL-4Ra) and the IL-13 receptor a1-chain (IL-13Ra1) can heterodimerize and form a receptor that binds either IL-4 or IL-13 and then activates the same transduction pathways in response to either cytokine (Aman et al., 1996; Galizzi et al., 1990; Idzerda et al., 1990) .
Although almost all biological eects of IL-4 and IL-13 are overlapping, these cytokines also exert speci®c eects. Unlike IL-13, IL-4 promotes the growth of activated T cells, mediated by an IL-4Ra/IL-2 receptor g-chain (gc) complex which binds only IL-4 (Takeshita et al., 1992) . No functional receptor complex solely speci®c for IL-13 has been identi®ed thus far. However another glycoprotein with high anity for IL-13 but which does not bind IL-4 has been described, and named the IL-13 receptor a2-chain (IL-13Ra2) (Caput et al., 1996) . IL-13Ra2 is a 380-amino acid protein with two consensus patterns characteristic of the hematopoietic cytokine receptor family (four conserved cysteines in the amino-terminal half of the extracellular domain and a WSXWS motif). The cytoplasmic domain of IL-13Ra2 is only 17 amino acid residues long and lacks signaling features such as Pro-rich sequences (box 1). IL-13Ra2 binds IL-13 with a K D of 250 pM when transfected alone in COS cells. This anity is not modulated by co-transfection of IL4Ra, and 125 I-IL-13 binding is not displaced by IL-4, suggesting that IL-4Ra and IL-13Ra2 do not oligomerize into a functional receptor complex in these cotransfected COS cells (Caput et al., 1996) . These observations raise the possibility that IL-13Ra2 may be a decoy receptor for IL-13 but not for IL-4 in cells expressing the IL-13Ra2 in addition to the functional receptor complex of IL-4Ra / IL-13Ra1. However, the fact that IL-13Ra2 participates in an additional functional receptor complex which mediates IL-13 speci®c biological activities has not been formally excluded.
Several reports indicate that some cytokines regulate the expression of their own receptor chains. For example, IL-2 induces IL-2Ra expression in lymphocytes and IL-4 increases IL-4Ra mRNA transcription in T cells (Harel-Bellan et al., 1986; Kotanides and Reich, 1996; Lecine et al., 1996) . In contrast, IL-13 and IL-4 down-regulate IL-4Ra and IL-13Ra1 expressions in monocytes . In this study, we report for the ®rst time that IL-13Ra2 mRNA expression is increased in response to IL-4 or IL-13 in the human keratinocyte cell line HaCaT. By binding and crosslinking experiments, we demonstrated that IL-13Ra2 is induced at the protein level in IL-4-treated HaCaT cells. We then characterized the signaling pathways activated in HaCaT cells by IL-4 or IL-13, and subsequently used inhibitors or constitutive active mutants of signal transduction proteins to identify the molecular mechanisms implicated in IL-13Ra2 induction by IL-4/IL-13.
Results

IL-4 and IL-13 induce IL-13Ra2 mRNA expression in the keratinocyte cell line HaCaT
In contrast to other established keratinocyte cell lines such as the widely used A431, the HaCaT cell line is non tumorigenic and has conserved a phenotype closely related to that of normal cells (Boukamp et al., 1988) . These HaCaT cells were ®rst evaluated in reference to their expression of the IL-4/IL-13 receptor components, as measured by RT ± PCR. As shown in Figure 1a , in serum-starved cells, mRNA for both IL4Ra and IL-13Ra1 are expressed in HaCaT cells, whereas mRNA for gc was undetectable (data not shown). Under these conditions, IL-13Ra2 mRNA was also undetectable, although increasing the number of PCR cycles (up to 35 as compared with 28) clearly indicated that some low level of mRNA was present. We then investigated whether IL-4 or IL-13 had any eect on the expression of these receptor chains. Serum-starved HaCaT cells were stimulated with IL-4 or IL-13 and RT ± PCR performed on RNA prepared at various time points. As seen in Figure 1a , no signi®cant variation was observed in the levels of expression of IL-4Ra nor of IL-13Ra1. In contrast, when cells were stimulated with IL-4 or IL-13, IL13Ra2 mRNA expression became detectable as early as 2 h and dramatically increased thereafter (Figure 1a ). Both cytokines induced a similar time course of expression, although, at the same concentration (10 ng/ml), IL-4 seemed to be a little more potent than IL-13 in inducing IL-13Ra2. The data on IL13Ra2 mRNA expression, as a function of IL-4 stimulation, was also gathered using a competitive PCR assay to actually quantitate message production. As can be seen in Figure 1b , the number of amplicons for the IL-13Ra2 was barely detectable in unstimulated cells and reached a high level at 8 h of cytokine stimulation. These data thus demonstrated that IL- HaCaT cells were stimulated with 10 ng/ml IL-4 or IL-13 for 1 to 24 h. mRNA were prepared and used as template for RT ± PCR experiments using speci®c probes for human IL-13Ra2, IL-13Ra1, or IL-4Ra. Competitive PCR quantitation of IL-13Ra2 mRNA in HaCaT cells stimulated with . HaCaT cells were either left unstimulated or exposed to IL-4 (10 ng/ml) over the course of 72 h. The dilution at which equivalence was reached in the competitive assay was used to calculate the number of amplicons within each sample per mg of total RNA utilized. Results represent the mean+s. I-IL-13 was detectable, which was not displaced by an excess of cold IL-4 or IL-13 (see Figure  2) . In IL-4 stimulated cells, measurable binding of native 125 I-IL-13 was detected after a 24 h stimulation, that consistently increased until 72 h (Figure 2 ). The speci®city of the binding was con®rmed by the observation that labeled IL-13 was displaced by an excess of cold IL-13. Interestingly,
125
I-IL-13 was not displaced by cold IL-4 indicating that the receptor binding this IL-13 was not the functional receptor formed by the dimerization of the IL-4Ra/IL-13Ra1. Indeed, the binding of IL-13 to the latter receptor has been previously shown to be readily displaced by either IL-4 or IL-13. In addition, the radiolabeling of native IL-13, used in this study, results in the production of a reagent that appears to only bind to the IL-13Ra2, in contrast to the modi®ed form of 125 I-IL-13-GYGY, which binds both IL-13Ra1 and IL-13Ra2 (see Materials and methods) (Vita et al., 1995) . These results suggest that the 125 I-IL-13 binding protein detected in response to IL-4 was IL-13Ra2 and not IL-13Ra1.
The magnitude of the binding was next evaluated by performing scatchard analysis on cytokine stimulated
HaCaT cells. After 72 h of stimulation with IL-4, radiolabeled ligand binding revealed the presence of 12 532 IL-13 receptors per cell, with a calculated K D of 294 pM, a value well in agreement with that described for IL-13Ra2 in transfected COS cells (Caput et al., 1996) . 
IL-4 and IL-13 signal transduction in keratinocytes
Since IL-13Ra2 expression was regulated by IL-4 and IL-13, we attempted to characterize the signal transduction pathways activated in HaCaT cells by these cytokines, especially IL-13 whose signaling pathways had never been investigated in any keratinocyte cell line.
Tyrosine phosphorylation of the JAK family kinases has been described after IL-4 and IL-13 stimulation in various cell types, although the participation of individual JAKs depends on the cell type considered. As shown in Figure 4a and b, both JAK1 and JAK2 were phosphorylated in HaCaT cells as early as 5 min and for at least 1 h following cytokine stimulation. No phosphorylation of TYK2 was detectable, and JAK3 was not expressed in these cells (data not shown). As an expected consequence of JAK activation, phosphorylation of STAT6 was observed upon IL-4 or IL-13 stimulation ( Figure 4c ).
We have previously described that in the A431 keratinocyte cell line, IL-4 not only activated the JAK/ STAT pathway, but also regulated the activity of various members of the MAPK family, in contrast to what has been described in most hematopoietic cells (Nelms et al., 1999) . We therefore investigated whether activation of ERK1/2 and p38 MAPK transduction pathways were triggered by IL-13 or IL-4 in HaCaT cells. Antibodies against the tyrosine and threonine phosphorylated forms of these kinases were used for this purpose. As shown in Figure 5a , both IL-4 and IL-13 induced a transient increase of ERK1/2 phosphorylation, peaking at 10 min after treatment. Activation of p38 MAPK was also observed with, however, a delayed kinetic response as compared to ERK ( Figure  5b ).
IL-4/IL-13-induced IL-13Ra2 mRNA expression involves JAK2, ERK and p38 MAPK Whether the signaling pathways described above might be involved in IL-13Ra2 induction in IL-4/IL-13-treated HaCaT was next assessed by speci®cally blocking these pathways by means of well described inhibitory compounds. Pretreatment of HaCaT cells with 10 mM of the JAK2 inhibitor AG490 (Meydan et al., 1996) dramatically reduced the IL-4/IL-13-induced IL-13Ra2 mRNA expression (Figure 6a,d ). The role of the MAPK pathways on IL-4/IL-13 induction of IL13Ra2 was also investigated using the MEK inhibitory derivative U0126 (Favata et al., 1998) and the p38 MAPK inhibitor SB203580 (Cuenda et al., 1995) . We found that a 1 h pretreatment of HaCaT cells with 25 mM U0126 completely abrogated IL-4/IL-13-induced IL-13Ra2 mRNA expression (Figure 6b,d) . In comparison, a weaker inhibition (*50%) of IL-4/IL-13-induced IL-13Ra2 mRNA expression was observed Figure 4 Eect of IL-4 and IL-13 on JAK1, JAK2 and STAT6 phosphorylation in HaCaT cells. Following IL-4 and IL-13 treatment, cell lysates were prepared and immunoprecipitated with antibodies against JAK1 (a), JAK2 (b) or STAT6 (c). The resulting complexes were washed ®ve times in lysis buer, electrophoresed and transferred to nitrocellulose membrane. The membrane was then hybridized with an anti-phosphotyrosine antibody (P-Tyr). To evaluate the amount of JAK1, JAK2 and STAT6 available on the blot for phosphorylation, each blot was stripped and re-probed with antibodies speci®c for the target proteins Figure 5 Eect of HaCaT stimulation with IL-4 and IL-13 on ERK1/2 and p38 MAPK activation. HaCaT cells were stimulated with IL-4 or IL-13. Cell lysates were prepared, electrophoresed and transferred to nitrocellulose membrane. The membrane was then hybridized with antibodies against either ERK1/2 (a) or p38 MAPK (b) phosphorylated on both tyrosine and threonine residues (p-ERK1/2 and p-p38 MAPK respectively). To evaluate the total amount of ERK and p38 MAPK present on the blot, each blot was stripped and re-probed with antibodies speci®c for the target proteins with the p38 MAPK inhibitor SB203580 (Figure 6c,d) , although the concentration used (10 mM) was optimal, as determined in parallel experiments.
Taken together, these results strongly suggest that the JAK2, ERK1/2 and p38 MAPK signaling pathways are involved in the regulation of IL-13Ra2 expression by IL-4 or IL-13.
Effects of constitutive active mutants of STAT6, MEK1 and MKK6 on IL-13Ra2 mRNA expression
To further examine the role of these signaling pathways in the regulation of IL-13Ra2 mRNA expression, we used gain-of-function mutants of STAT6, MEK1 and MKK6, which constitutively activate the STAT6, ERK1/2 and p38 MAPK pathways, respectively. Plasmids coding for Flag-tagged STAT6VT, HAtagged MEK1DD (Brunet et al., 1994) and Flagtagged MKK6EE (Raingeaud et al., 1996) were transiently expressed. Expression of gain-of-function mutants in HaCaT transfectants was visualized by Western blotting with antibodies against the tag epitopes (Flag for STAT6VT and active MKK6, HA for active MEK1) (Figure 7a , upper panels).
In STAT6VT transfectants, immunoprecipitation experiments revealed a constitutive tyrosine phosphorylation of STAT6 (Figure 7a lower panel) , as previously described in other cell lines (Daniel et al., 2000) . Subsequently, the transcriptional potential of STAT6VT was assessed using an IL-4 inducible luciferase reporter construct carrying ®ve copies of Figure 6 Eect of pharmacological inhibitors on IL-4/IL-13-induced IL-13Ra2 expression. HaCaT cells were pretreated with either AG490 (10 mM) for 16 h (a), U0126 (25 mM) for 1 h (b), or SB203580 (10 mM) for 1 h (c) in serum-free medium. Cells were then stimulated with IL-4 or IL-13 for 3 ± 8 hours. Corresponding total mRNA were extracted, reverse transcribed, and ampli®ed by PCR using IL-13Ra2 speci®c primers. Ampli®cation products were then electrophoresed on agarose gels (a, b and c), or on nondenaturated polyacrylamide gel stained with Vistra Green, and quanti®ed with a Storm Fluorlmager (d, data reported in arbitrary units) (Ezernieks et al., 1996) . In unstimulated STAT6VT expressing cells, detectable transcriptional activity was observed, which was strongly potentiated by IL-4 (data not shown). Expression of STAT6VT in the absence of stimulation did not signi®cantly modify the IL-13Ra2 mRNA expression level. Interestingly, when the cells were stimulated with IL-4 or IL-13, IL-13Ra2 mRNA expression was clearly higher in STAT6VT expressing cells than in non transfected cells (Figure 7b ). As expected, active MEK1 or MKK6 induced activation of ERK or p38 MAPK, respectively, as shown with antibodies against the phosphorylated forms of these two kinases (Figure 7a lower panels) . In contrast to STAT6VT, active mutants of MEK1 or MKK6 increased expression of IL-13Ra2 mRNA, even in the absence of cytokine stimulation (Figure 7b) , and no apparent synergy with IL-4 or IL-13 could be evidenced. Thus, the transient transfection experiments using gain-of-function mutants indicated that STAT6, MEK1, and MKK6 activities could regulate IL-13Ra2 mRNA expression. These results are consistent with those obtained with the speci®c inhibitors and further support the idea that the JAK/STAT, ERK1/2 and p38 MAPK pathways are implicated in IL-4 / IL-13-induced IL-13Ra2 mRNA expression.
Discussion
IL-4 and IL-13 biological eects are mediated by a shared receptor composed of the IL-4Ra and the IL13Ra1 receptor chains, expressed on a variety of cell types. Evaluation of regulation of receptor composition has largely focused on cells of hematopoietic lineage. IL-4Ra expression has been shown to be increased in T lymphocytes by exposure to IL-4 (Kotanides and Reich, 1996) . Immunoglobulin receptor crosslinking induces an upregulation of the IL-4Ra while combined ligation of the immunoglobulin and CD40 receptors induces the IL-13Ra1 in B lymphocytes (Ogata et al., 1998) . IL-4 and IL-13 themselves down-regulate their own receptor expression in monocytes ).
An additional receptor chain, the IL-13Ra2, has been shown to bind IL-13 with picomolar anity. High level expression of the IL-13Ra2 has been reported in synovial ®broblasts, high grade glioblastomas and renal cell carcinomas (Debinski et al., 1996; Feng et al., 1998) , where its cellular expression has been shown to be constitutive. Conditions modulating the surface expression of this receptor chain were investigated herein for the ®rst time. Since keratinocytes respond to IL-4 and IL-13, we investigated whether these cytokines were able to regulate the expression of their own receptor components. In contrast to IL-4/IL-13 receptor regulation previously reported in hematopoietic cells, no variations of IL-4Ra or IL-13Ra1 mRNA expression were induced by these cytokines in the keratinocyte cell line HaCaT. On the contrary, a strong induction of IL-13Ra2 expression by IL-4 or IL-13 was evidenced at both the mRNA and protein level.
The This anity is consistent with that previously described for the IL-13Ra2 in other cell types, as is the 55 kDa estimate for receptor size as determined by immunoprecipitation (Caput et al., 1996) . Con®rma-tion that the radiolabeled ligand was in fact binding to the IL-13Ra2 was done using several receptor speci®c antibodies where it seems that only the antibody to the IL-13Ra2 was capable of immunoprecipitating labeled ligand. Induction of IL-13Ra2 mRNA in response to IL-4 or IL-13 was also observed in two other keratinocyte cell lines (A431 and SVK14), but not in some other IL-4/IL-13 responsive cells, such as the breast cancer cell line MDA-MB-231, nor in the monocytic cell line THP1 (unpublished observations). A larger range of cell types need to be studied to determine whether the regulation of the IL-13Ra2 by IL-4 and IL-13 is restricted to the keratinocyte lineage.
Dierences in IL-13Ra2 mRNA regulation by IL-4 or IL-13, depending on the cell type considered, might be related to a variability in the signal transduction pathways triggered by IL-4 and IL-13. As described in other cell lines, JAK1 and JAK2 were activated in IL-4/IL-13-treated HaCaT cells. JAK2 involvement in IL-4/IL-13-induced IL-13Ra2 mRNA expression was assessed using AG490 JAK2 inhibitor (Meydan et al., 1996) . AG490 has been also described to inhibit JAK3 (Wang et al., 1999) . However, as HaCaT cells are devoid of JAK3, the AG490 inhibitory eect on IL-4/ IL-13-induced IL-13Ra2 mRNA expression is speci®c for JAK2. JAK2 involvement in IL-4/IL-13-induced IL-13Ra2 mRNA expression could be due to either phosphorylation of STAT6, thereby directly enhancing IL-13Ra2 transcription, or by phosphorylating one or more tyrosine residues on the IL-4/IL-13 receptor chains or adaptator molecules, allowing the recruitment of other transduction pathways. Further investigation aimed at understanding the role of JAK2 in IL-4/IL-13-induced IL-13Ra2 mRNA expression is currently in progress.
STAT6 is implicated in the transcriptional regulation of several IL-4/IL-13 responsive genes, such as the IL4Ra, class II major histocompatibility molecules and IgE germline genes (Shimoda et al., 1996; Takeda et al., 1996) . Whether STAT6 is implicated in IL-13Ra2 induction was assessed using a gain-of-function mutant of STAT6 (Daniel et al., 2000) . This constitutive active mutant, STAT6VT, was not sucient alone to induce IL-13Ra2 mRNA expression, but strongly potentiated the induction triggered by IL-4 and IL-13. This is consistent with the IL-4/IL-13 potentiation of the transcriptional activity of STAT6VT, as determined with the IL-4 inducible luciferase reporter construct. These data suggest that the STAT6VT mutant is not fully active in HaCaT keratinocytes, and that the activation of another signaling pathway in response to IL-4 or IL-13 is required to induce its transcriptional activity. It cannot, however, be formally excluded that STAT6 transcriptional activity is not sucient to induce IL-13Ra2 expression, and that IL-4 and IL-13 stimulation led to the activation of another signaling pathway which, coordinately with STAT6, participates in IL-13Ra2 regulation.
In addition to JAK/STAT6 activation, IL-4 and IL-13 also triggered an activation of ERK1/2 and p38 MAPK in these cells. The MEK1/2 speci®c inhibitor U0126 strongly decreased the induction of IL-13Ra2 in response to IL-4 and IL-13. In addition, expression of a constitutive active mutant of MEK1, which activates ERK1/2, was sucient to induce IL-13Ra2 mRNA expression in unstimulated cells. These data indicate that the MEK1 ± ERK1/2 pathway regulates IL-13Ra2 mRNA expression and participates in its induction by IL-4 and IL-13.
The p38 MAPK inhibitor SB203580 also had an inhibitory eect (*50% decrease) on IL-4/IL-13-induced IL-13Ra2 mRNA expression. SB203580 has been shown to inhibit only the a and b but not the g and d isoforms of p38 MAPK (Kumar et al., 1997) , while all four p38 MAPK mRNA were detectable by RT ± PCR in HaCaT cells (data not shown). Expression of a constitutive active mutant of MKK6, the upstream activator of the four isoforms of p38 MAPK, leads to IL-13Ra2 mRNA expression in unstimulated cells. Thus, the p38 MAPK pathway is implicated in the regulation of IL-13Ra2 mRNA expression. However, the p38 MAPK isoforms involved in its induction by IL-4 and IL-13 in HaCaT cells remain to be identi®ed. IL-4 and IL-13 are not potent activators of ERK and p38 MAPK in most of cell types (Nelms et al., 1999) . Thus, it is tempting to postulate that this IL-4/IL-13-induced MAPKs activation might explain the dierences in IL-13Ra2 regulation observed between keratinocytes and some other cell lines.
IL-13Ra2 induction in response to IL-4 and IL-13 may involve both transcriptional and/or post transcriptional regulation. STAT6 together with the transcription factors phosphorylated by ERK and p38 MAPK may directly participate to the regulation of IL-13Ra2 gene transcription. Characterization of the IL-13Ra2 promoter sequence should provide leads to further investigate the transcriptional regulation of this receptor chain. In addition, p38 MAPK activation has also been described to be involved in mRNA stabilization (Chen et al., 1998; Ming et al., 1998; Winzen et al., 1999) . In particular, we have previously shown that activation of p38 MAPK in IL-4-stimulated keratinocyte A431 has a critical role in IL-6 mRNA stabilization cell lines (Wery-Zennaro et al., 2000) . A role for p38 MAPK in the stabilization of IL-13Ra2 may be suggested, yet remains to be determined.
The present work demonstrates that IL-4 and IL-13 induce IL-13Ra2 expression at both the mRNA and protein levels in keratinocytes, and that the ERK1/2 and p38 MAPK together with JAK2 and STAT6 participate in this process. The function of IL-13Ra2 is still debatable, and the physiological consequences of its upregulation in keratinocytes in response to IL-4 and IL-13 remains to be determined.
Materials and methods
Cytokines, antibodies and reagents
Human recombinant IL-13 and IL-4, either kindly provided by Dr N Vita (Sano®, France) or purchased from Peprotech (Rocky Hill, NJ, USA), were added to the culture medium at 10 ng/ml. Anti-JAK1 (ref. Anti-ERK1/2 monoclonal antibody was purchased from Zymed (San Francisco, CA, USA) and anti-p-ERK1/2 or anti-p-p38 MAPK polyclonal antibodies were from Biolabs (Beverly, MA, USA). Flag speci®c antibody (M2) was from Sigma Aldrich (St. Louis, MO, USA). Anti-IL-13Ra1 and anti-IL-13Ra2 were produced in collaboration with Zymed (San Francisco, CA, USA). The anity puri®ed antisera were produced against either the amino-terminal amino acids (N-15, aa 62 ± 76) or the carboxy-terminal amino acids (C-19, aa 379 ± 397) of IL-13Ra1. Anity puri®ed antisera against IL-13Ra2 was prepared against the carboxy-terminal amino acids (C-12, aa 364 ± 375) of the deduced protein sequence. Inhibitors AG490 and SB203580 were purchased from Calbiochem (Darmstadt, Germany). U0126 was from Promega (Madison, WI, USA).
Cell culture
The human keratinocyte cell line HaCaT (Boukamp et al., 1988) was cultured in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 1 mM sodium pyruvate and 10% fetal calf serum (FCS). In speci®c experiments described below, cells were serum-starved for 24 h before treatment with IL-4 or IL-13. 728C (for 2 min). PCR products were either run on a 2% agarose gel or on a 5% non-denaturing polyacrylamide gel, stained with Vistra Green (Amersham Pharmacia Biotech, Uppsala, Sweden), and quanti®ed with a Storm Fluorlmager (Molecular Dynamics, Inc., Uppsala, Sweden). Competitive PCR was performed as previously described (Ford et al., 1999) . Primers utilized for the IL-13Ra2 competitive studies were GAGGAGAGGCAATATCAAGG and GGCCAT GACTGGAAACTGT. The primer utilized for the competitive substrate was GGCCATGACTGGAAACTGTTCAAC TGTAGCAGTCACCAAGGTAT. The IL-13Ra2 full length product measured 1230 bp with the competitive substrate measuring 922 bp.
Radiolabeling and binding of native IL-13
125 I labeling of IL-13 has previously been performed by two separate procedures, one using native IL-13, the other utilizing IL-13 where the 43rd aminoacid, tyrosine, has been replaced by phenylalanine and a glycine-tyrosine-glycine-tyrosine tag added at the C-terminus (Vita et al., 1995) . Prior experimentation has revealed that 125 I-IL-13 GYGY will bind to either IL13Ra1 or IL-13Ra2 (Caput et al., 1996; Ogata et al., 1998) . Work presented herein and information in prior reports suggest that native IL-13, subsequent to the conditions needed for iodination, readily binds to the IL-13Ra2 with limited, if any, binding to the IL-13Ra1 (Murata et al., 1997) . Whether this variance is due to dierences in the chemical processes utilized with individual iodination protocols or to structural alterations has not been determined. Given that the present study was speci®cally directed at the IL-13Ra2, we chose to utilize native IL-13 for radiolabeling. Native IL-13 (2.5 mg) was labeled using Iodogen 1 reagent pre-coated tubes (Pierce, Rockford IL, USA). Brie¯y, 500 mCi Na 125 I (NEN Life Sciences, Boston MA, USA) was activated and added to IL-13 in potassium phosphate buer (PBS). The reaction was allowed to proceed for 15 min and was then quenched with a tyrosine scavenging buer. The reaction mixture was then desalted on a D-Salting 6000 MW cut-o column in 500 ml fractions. Fractions were analysed by gamma counting and SDS ± PAGE autoradiographic densitometry to determine speci®c activity, which routinely ranged from 40 ± 50 mCi/mg. For 125 I-IL-13 binding assays, 1610 6 cells were seeded in 6-well tissue culture dishes and cultured in the presence or absence of IL-4 for the periods of time speci®ed. Binding was assessed in the presence or absence of excess unlabeled ligands, which were added for 15 ± 20 min prior to the addition of the labeled ligand. The cell monolayer was solubilized in 1N NaOH and counted on a mini-gamma counter. All experiments were done in duplicate.
Affinity crosslinking of receptor complexes
Crosslinking was performed essentially as previously described (Ogata et al., 1998) . Brie¯y, HaCaT cells (2610   6   ) were seeded in 100 mm tissue culture dishes for 24 h. IL-4 was added at 10 ng/ml for 72 h to allow the expression of the IL-13Ra2 receptor. The attached cells were washed twice with cold PBS and incubated with or without unlabeled IL-13 (200-fold excess) for 20 min at 48C in RPMI binding buer (RPMI+0.3% BSA) prior to the addition of labeled ligand.
125 I-IL-13 (250 pM) was then added for 2 ± 3 h at 48C. The plates were then washed four times with cold PBS and crosslinked in the presence of 1 mM BS 3 (Bis (sulfosuccinimidyl) Suberate) for 20 min, quenched with 10 mM Tris pH 7.5 and washed twice in cold PBS. The washed cells were scraped into 7.5 ml PBS and centrifuged at 570 g to pellet the cells. The cells were then re-suspended in 200 ml lysis buer (50 mM HEPES pH 7.5, 0.5% Brij 97, 50 mM NaCl, 50 mM NaF, 5 mM EDTA, 1 mM Na 3 VO 4 , 20 mM iodoacetamide, 50 mM aminocaproic acid, 2% protease inhibitor cocktail) (Sigma, St. Louis, MO, USA), incubated for 30 min on ice, and centrifuged for 15 min. at 14 000 g at 48C. Supernatants, 100 ml each point, were either boiled in Laemmli buer and analysed by 7.5% SDS ± PAGE or were further immunoprecipitated with appropriate antibodies as described above.
Scatchard analysis of IL-4 treated HaCaT cells
Scatchard analysis was performed essentially as described, with modi®cations for adherent cells (Ogata et al., 1998) . Samples were counted on a standard mini gamma counter with a 76.1% counting eciency. The dissociation constant (K D ) of the labeled ligand was determined according to the procedures of Munson and Rodbard (1980) .
Immunoprecipitation and Western blotting
After stimulation with IL-4 or IL-13, cell lysates were prepared as previously described (Wery-Zennaro et al., 1999) . For immunoprecipitation experiments, 1 mg of cell lysates were incubated with appropriate antibody and protein A-Sepharose beads at 48C. The immunoprecipitates were separated through 8% SDS ± PAGE. Proteins were transferred to Hybond-C extra membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). Membranes were hybridized with the appropriate antibodies. The blots were developed using the enhanced chemiluminescence assay (Amersham Pharmacia Biotech, Uppsala, Sweden).
Plasmids
The plasmids pECE S218D/S222D MEK1 (MEK1DD) and pcDNA3 S189E/S207E MKK6 (MKK6EE) were previously described (Brunet et al., 1994; Raingeaud et al., 1996) . The construct encoding Flag-h-STAT6 was generated by PCR from pXMSTAT6 (Moriggl et al., 1997) with an upper primer (TCTCTGTGGGGTCTGGTC) and a lower primer (CCGCTCGAGTCACCAACTGGGGTT). The PCR fragment was then cut with XhoI and inserted in frame with the Flag Tag into the XhoI-blunt ended Bglll pCMV-Tag1 (Stratagene, La Jolla, CA, USA). The double mutant STAT6VT was prepared by introducing two alanine residues at amino acid positions 547 and 548 (Daniel et al., 2000) by using the Quick Change site directed mutagenesis kit (Stratagene, La Jolla, CA, USA). The correct nucleotide sequences of PCR products and cloning junctions were veri®ed by DNA sequencing.
Transfection experiments
HaCaT cells were harvested by trypsinization, pelleted, and resuspended in an electroporation medium containing 10 mM KCl, 0.15 mM CaCl 2 , 10 mM K 2 HPO 4 /KH 2 PO 4 pH 7.6, 25 mM HEPES pH 7.6, 2 mM EGTA pH 7.6, 5 mM MgCl 2 , 5 mM glutathione and 2 mM ATP. For electroporation, 10 7 cells were mixed with 10 mg of DNA and pulsed at 280 V and 1000 mF (Gene Pulser II, Bio-Rad, Hercules, CA, USA). Electroporated cells were then plated into DMEM containing 10% FCS during 24 h, serum-starved during 12 h and stimulated with IL-4 or IL-13 or left without cytokine exposure.
